BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Beta Bionics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$16.84+0.49 (+3.00%)
Close on Oct 19, 2026
- Market cap
- $750.14M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.18 (−15.88%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Beta Bionics, Inc. grew revenue 52.5% to $119.01M over the twelve months to Jun 30, 2026. Free cash flow was -$61.41M.
Revenue
$119.01M
+52.5% vs. a year earlier
Operating income
-$83.02M
TTM Q2 2026
Free cash flow
-$61.41M
TTM Q2 2026
EPS, diluted
-$1.65
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $750.14M
- P/E ratio
- –
- Price to sales
- 6.30
- Price to book
- 2.93
- Dividend yield
- –
- Free cash flow yield
- -8.19%
Fundamentals
- Revenue
- $119.01M
- Net income
- -$72.97M
- EPS, diluted
- -$1.65
- Free cash flow
- -$61.41M
- Book value per share
- $5.76
- Diluted shares
- 45M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$119.01M+52.5% YoY
Gross profit
$69.40M+64.9% YoY
Operating income
-$83.02M
Net income
-$72.97M
EPS, diluted
-$1.65
Free cash flow
-$61.41M
Reported periodTrailing twelve months